AU2017372377B2 - Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors - Google Patents

Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors Download PDF

Info

Publication number
AU2017372377B2
AU2017372377B2 AU2017372377A AU2017372377A AU2017372377B2 AU 2017372377 B2 AU2017372377 B2 AU 2017372377B2 AU 2017372377 A AU2017372377 A AU 2017372377A AU 2017372377 A AU2017372377 A AU 2017372377A AU 2017372377 B2 AU2017372377 B2 AU 2017372377B2
Authority
AU
Australia
Prior art keywords
compound
6alkyl
heteroaryl
heterocyclyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017372377A
Other languages
English (en)
Other versions
AU2017372377A1 (en
Inventor
Jing Li
Zhiwei Wang
Haibo Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of AU2017372377A1 publication Critical patent/AU2017372377A1/en
Application granted granted Critical
Publication of AU2017372377B2 publication Critical patent/AU2017372377B2/en
Priority to AU2022203737A priority Critical patent/AU2022203737A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017372377A 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors Ceased AU2017372377B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203737A AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
CNPCT/CN2016/108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203737A Division AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Publications (2)

Publication Number Publication Date
AU2017372377A1 AU2017372377A1 (en) 2019-07-18
AU2017372377B2 true AU2017372377B2 (en) 2022-03-03

Family

ID=62491736

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017372377A Ceased AU2017372377B2 (en) 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors
AU2022203737A Abandoned AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022203737A Abandoned AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Country Status (16)

Country Link
US (2) US11136323B2 (https=)
EP (1) EP3551630A4 (https=)
JP (2) JP7064495B2 (https=)
KR (1) KR20190091339A (https=)
CN (2) CN110267959B (https=)
AU (2) AU2017372377B2 (https=)
BR (1) BR112019011847A2 (https=)
CA (1) CA3045959A1 (https=)
EA (1) EA201991355A1 (https=)
IL (2) IL266986B (https=)
MX (1) MX394882B (https=)
NZ (1) NZ754944A (https=)
SG (1) SG10201912192RA (https=)
TW (2) TW202233190A (https=)
WO (1) WO2018103688A1 (https=)
ZA (1) ZA201903286B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
JP2023503230A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Ｐｉ３ｋデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
KR20240060647A (ko) * 2021-09-14 2024-05-08 베이진 엘티디 Btk 저해제와 pi3 키나제 저해제의 조합물을 이용하는 암 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175195A1 (en) 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
EP2802586B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20210317140A1 (en) * 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cas Registry Number 1025939-56-3; STN Entry Date 6 June 2008 *

Also Published As

Publication number Publication date
US20220098202A1 (en) 2022-03-31
TW202233190A (zh) 2022-09-01
EA201991355A1 (ru) 2019-11-29
US20190367523A1 (en) 2019-12-05
TWI762534B (zh) 2022-05-01
EP3551630A4 (en) 2020-07-15
EP3551630A1 (en) 2019-10-16
AU2022203737A1 (en) 2022-06-23
CN114805366A (zh) 2022-07-29
CN110267959B (zh) 2022-05-27
IL290419B2 (en) 2023-02-01
US11136323B2 (en) 2021-10-05
KR20190091339A (ko) 2019-08-05
WO2018103688A1 (en) 2018-06-14
IL266986A (en) 2019-07-31
ZA201903286B (en) 2021-01-27
JP2022090051A (ja) 2022-06-16
CA3045959A1 (en) 2018-06-14
SG10201912192RA (en) 2020-02-27
BR112019011847A2 (pt) 2019-10-29
MX394882B (es) 2025-03-24
IL290419A (en) 2022-04-01
IL290419B (en) 2022-10-01
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
IL266986B (en) 2022-03-01
CN110267959A (zh) 2019-09-20
AU2017372377A1 (en) 2019-07-18
JP7064495B2 (ja) 2022-05-10
NZ754944A (en) 2023-02-24
JP2020500909A (ja) 2020-01-16
TW201833113A (zh) 2018-09-16

Similar Documents

Publication Publication Date Title
AU2017372377B2 (en) Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors
AU2017206820B2 (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
ES2907622T3 (es) Compuestos de heteroarilo como inhibidores de BTK y usos de estos
JP2017527561A (ja) リジン特異的なデメチラーゼ−１の阻害剤
ES2944658T3 (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de PI3Kdelta
TW202214634A (zh) 雜環化合物及其衍生物
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
HK40088309A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
BR102019005173A2 (pt) Composto de pirido de anel aromático de cinco elementos, método de preparação do mesmo e uso do mesmo
HK40029822B (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40029822A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)